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1. Introduction 
Neuroendocrine tumors, or more properly gastro-entero-pancreatic tumors (GEP-NETs), are 
cancers of the interface between the endocrine (hormonal) system and the nervous system. 
A neuroendocrine tumor begins in the hormone-producing cells of the body’s 
neuroendocrine system, which is made up of cells that are a cross between traditional 
endocrine cells (or hormone-producing cells) and nerve cells. Neuroendocrine cells are 
found throughout the body in organs, such as the lungs and gastrointestinal tract (such as 
the stomach and intestines), and perform specific functions, such as regulating the air and 
blood flow through the lungs and controlling the speed at which food is moved through the 
gastrointestinal tract (1). 
2. NETs epidemiology and characteristics 
Neuroendocrine tumors (NETs) are rare, slow-growing neoplasms characterized by their 
ability to store and secrete different peptides and neuroamines. Some of these substances 
cause specific clinical syndromes, whereas other may have elevated plasma or urine levels 
that are not associated with specific syndromes or symptom complexes. The biochemical 
markers are those hormones or amines secreted by the neuroendocrine cells from which 
these tumors are derived. Some of these are not specific to any tumor, but are produced and 
secreted by most NETs, whereas other biochemical markers are more specific to the type of 
tumor and where their quantification can lead to the suspicion or confirmation of the 
presence of such a tumor (2). There are many types of neuroendocrine tumors, such as: 
pheochromocytoma, Merkel cell cancer, and neuroendocrine carcinoma, and also other 
types of cancer that begin in hormone-producing cells, including endocrine tumors, 
carcinoid tumors, thymoma, thyroid cancer, and islet cell tumors. Approximately 60% of 
neuroendocrine tumors are not able to be described as a specific type of cancer other than 
neuroendocrine carcinoma. Neuroendocrine carcinoma can be found in a number of places 
in the body, including the lungs, brain, and gastrointestinal tract. The annual incidence of 
NETs has risen to 40 to 50 cases per million, perhaps because of better diagnosis and the 
availability of highly specific and sensitive ways to measure these tumors products, improved 
immunohistochemistry, and enhanced techniques for tumor detection (3). There are a number 
of impediments to the diagnosis of these tumors. They are rare, comprising less than 2% of 
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gastrointestinal (GI) malignancies, and are therefore not high on the list of causes of specific 
symptom complexes. Symptoms themselves are often nonspecific and do not lend themselves 
readily to identifying the specific underlying tumor. In addition, the manifestations are 
protean and mimic a variety of disorders. Tumors may be found incidentally on laparoscopy 
for abdominal pain or during the surgical removal of an appendix or even during a 
computerized tomographic scan of the abdomen for unexplained symptoms (3,4). 
3. Classification of GEP-NETs by site of origin and by symptoms 
The clinical behavior of NETs is extremely variable; they may be functioning or not 
functioning, ranging from very slow-growing tumors (well-differentiated NETs), which are 
the majority, to highly aggressive and very malignant tumors (poorly differentiated NETs) (5).  
 
Classification 
Biological 
behavior 
Metastases 
Ki-67 
index 
(%)†  
Histological 
differentiation
Infiltration/ 
angioinvasion 
Tumor 
size (cm) 
Well-
differentiated 
NET 
Benign –‡; ±§  <2 Well – ≤1 
Well-
differentiated 
neuroendocrine 
carcinoma 
Low 
malignancy 
± >2 Well + >2‡; >3§  
Poorly-
differentiated 
neuroendocrine 
carcinoma 
High 
malignancy 
+ >30 Poor + Any size 
†Identical to MIB1. 
‡Gastrointestinal neuroendocrine tumor. 
§Pancreatic neuroendocrine tumor. 
NET: Neuroendocrine tumor. 
Table 1. WHO classification of neuroendocrine tumors. 
3.1 Nonfunctioning NETs 
Nonfunctioning NETs are not associated with a distinct hormonal syndrome so are more 
difficult to detect than functioning NETs; owing to this, patients generally present late with 
large primary tumors and advanced disease. However, nonfunctioning NETs may secrete 
bioactive hormones or amines at subclinical levels, or secrete compounds that lead to other, 
still under-recognized hormonal syndromes. They can also cause nonspecific symptoms 
related to increased tumor mass and/or metastases such as weight loss, bleeding or 
abdominal pain. 
3.2 Functioning NETs 
NETs can arise in different organs and from different cell types and so present a clinical 
challenge to physicians owing to their diversity and the variety of symptoms they cause. 
www.intechopen.com
 A Rare Gastric Carcinoma - Neuroendocrine Tumors 
 
131 
Functioning NETs are characterized by the hormones they produce and/or the symptoms 
they cause; clinical symptoms are typically observed following metastasis to the liver. 
3.3 GEP-NETs classification 
The vast majority of GEP-NETs fall into two nearly distinct categories: carcinoids, and 
pancreatic endocrine tumors (PETs). Despite great behavioral differences between the two, 
they are grouped together as GEP-NETs because of similarities in cell structure. PETs (1-2% 
of all pancreatic tumors) may secrete hormones (as a result, perhaps, of impaired storage 
ability), and those hormones can wreak symptomatic havoc on the body. Those PETs that do 
not secrete hormones are called nonfunctioning tumors. Secretory (functioning) tumors  are 
classified by the hormone most strongly secreted – for example, insulinoma, which produces 
excessive insulin, and gastrinoma, which produces excessive gastrin. Carcinoid tumors are 
further classified, depending on the point of origin, as foregut (lung, thymus, stomach, and 
duodenum) or midgut (distal ileum and proximal colon) or hindgut (distal colon and 
rectum). Less than one percent of carcinoid tumors originate in the pancreas. But for many 
tumors, the point of origin is unknown. Carcinoid tumors tend to grow much more slowly 
than PETs (2,6).  
3.4 Carcinoid syndrome  
A carcinoid tumor may produce serotonin (5-HT), a biogenic amine that causes a specific set 
of symptoms including 
 flushing 
 diarrhea or increase in number of bowel movements 
 weight loss 
 weight gain 
 heart palpitations 
 congestive heart failure (CHF) 
 asthma 
 acromegaly 
 Cushing's syndrome 
This set of symptoms is called carcinoid syndrome which occurs in approximately 10% of 
patients with metastatic NETs. It is characterized by flushing (63–94% of patients), diarrhea 
(68–84%), abdominal pain (10–55%), telangiectasia (25%) and bronchoconstriction (3–19%). 
Carcinoid crisis is the most immediate life-threatening complication of carcinoid syndrome 
and is thought to result from a massive release of bioactive products from the tumor. Crises 
can occur spontaneously, but often arise in response to stress, anesthesia, chemotherapy or 
surgery. Symptoms are an exacerbation of the usual clinical symptoms of carcinoid 
syndrome, including severe flushing with or without bronchospasm, tachycardia and 
hypo/hypertension. Failure to effectively manage carcinoid syndrome can lead to exposure 
of the heart to high levels of vasoactive substances released from hepatic metastases, which 
causes carcinoid heart disease; between 10–20% of patients with carcinoid syndrome have 
heart disease at diagnosis. Carcinoid heart disease is characterized by plaque-like, fibrous 
thickening of the endocardium (classically on the right side of the heart); tricuspid and 
pulmonary valves; right-sided carcinoid heart disease is associated with substantial 
morbidity and mortality (7-10).  
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3.5 Summary of GEP - NETs classification (2,11,12) 
 carcinoids (about two thirds of GEP-NETs)  
 with carcinoid syndrome (about 10 percent of carcinoids) 
 without carcinoid syndrome (about 90 percent of carcinoids) 
 PET s (about one third of GEP-NETs)  
 nonfunctioning (15 to 30 percent of PETs) 
 functioning (70 to 85 percent of PETs)  
 gastrinoma, producing excessive gastrin and causing Zollinger-Ellison 
Syndrome (ZES) 
 insulinoma, producing excessive insulin 
 glucagonoma, producing excessive glucagon 
 vasoactive intestinal peptideoma (VIPoma), producing excessive vasoactive 
intestinal peptide (VIP) 
 PPoma, producing excessive pancreatic polypeptide (often classed with 
nonfunctioning PETs) 
 somatostatinoma, producing excessive somatostatin 
 watery diarrhea, hypokalemia-achlorhydria (WDHA) 
 CRHoma, producing excessive corticotropin-releasing hormonse (CRH) 
 calcitoninoma, producing excessive calcitonin 
 GHRHoma, producing excessive growth-hormone-releasing hormone (GHRH) 
 neurotensinoma, producing excessive neurotensin 
 ACTHoma, producing excessive adrenocorticotropic hormone (ACTH) 
 GRFoma, producing excessive Growth hormone-releasing factor (GRF) 
 parathyroid hormone–related peptide tumor 
 Other NETs  
 medullary carcinoma of the thyroid 
 Merkel cell cancer (trabecular cancer) 
 small-cell lung cancer (SCLC) 
 large-cell neuroendocrine carcinoma (of the lung) 
 extrapulmonary small cell carcinomas (ESCC or EPSCC)in general 
 neuroendocrine carcinoma of the cervix 
 Multiple Endocrine Neoplasia type 1 (MEN-1 or MEN1) (usually nonfunctioning) 
(also causing ZES) 
 Multiple Endocrine Neoplasia type 2 (MEN-2 or MEN2) 
 neurofibromatosis type 1 
 tuberous sclerosis 
 von Hippel-Lindau (VHL) disease 
 neuroblastoma 
 pheochromocytoma (phaeochromocytoma) 
 paraganglioma 
 neuroendocrine tumor of the anterior pituitary 
 Carney's complex 
4. Metastases and malignancy 
GEP-NETs are often malignant, since the primary site often eludes detection for years, 
sometimes decades – during which time the tumor has the opportunity to metastasize. The 
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most common metastatic sites are the liver, the lymph nodes, and the bones. Liver 
metastases are so frequent and have such prominent blood supply that for many patients, 
they dominate the course of the cancer (13).   
5. Well-differentiated neuroendocrine (carcinoid) tumors of the stomach 
Neuroendocrine tumors (NETs) of the stomach comprise less than 1% of gastric neoplasms. 
In the pre-endoscopy era,they comprised 1.9% of all carcinoids, but in more recent studies, 
10% to 30% of all carcinoids are reported in the stomach. They can be subclassified into 3 
distinct groups: those associated with chronic atrophic gastritis/pernicious anemia (type 1; 
70%-80%), those associated with Zollinger-Ellison syndrome (ZES) with multiple endocrine 
neoplasia type I (MEN I) (type 2; 5%), and sporadic NETs of the stomach (type 3; 15%-20%) 
(13-15).  
5.1 Etiology 
Both types 1 and 2 NETs of the stomach are associated with hypergastrinemia (Table 2). 
High levels of gastrin are thought to result in hyperplasia of the enterochromaffin-like cells 
in the stomach, ultimately leading to hyperplastic lesions and small, often multiple carcinoid 
tumors. In contrast to types 1 and 2 carcinoids, type 3 carcinoids develop in the absence of 
hypergastrinemia and tend to pursue an aggressive clinical course. Type 1 carcinoids are 
generally small and frequently multiple; limited to the mucosa-submucosa, and metastases 
occur in less than 2.5% to lymph nodes and less than 2.5%% to the liver. Type 2 carcinoids 
are almost always multiple and generally small (<1 cm) and are usually limited to the 
mucosa-submucosa, but are slightly more aggressive than type 1 carcinoids, with up to 30% 
showing lymph node metastases, and up to 10% may show liver metastases.Type 3 
carcinoids are usually single, generally larger (>1 cm in 70%), and invasive through the 
submucosa and deeper in most cases (>75%); 70% had accompanying lymph node 
metastases, and 69% had distant metastases (16,17).  
 
 Hypergastrinemia
Gastric 
acid 
Secretion
Typical 
Size, cm 
No. tumors Clinical Features 
Type 1 (in 
setting of chronic 
atrophic gastritis 
type A) 
Yes (as a result of 
achlorhydria) 
Low < 1 Multifocal 
Rarely invasive; 
endoscopic removal often 
adequate 
Type 2 (in 
setting of ZES) 
Yes (as a result of 
ectopic gastrin 
secretion) 
High < 1 Multifocal 
Rarely invasive; may 
respond to somatostatin 
analogs 
Type 3 
(sporadic) 
No Normal > 1 Solitary 
Frequently invasive and 
metastatic 
Table 2. Types of gastric NETs 
5.2 Pathological classification 
In general, NETs of the stomach and other NETs are divided into well-differentiated and 
poorly differentiated categories. The concept of differentiation is linked to the grade of the 
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tumors (see below), but there are subtle differences between differentiation and grade. 
Differentiation refers to the extent to which the neoplastic cells resemble their nonneoplastic 
counterparts. In NETs, well-differentiated examples have characteristic "organoid" 
arrangements of the tumor cells, with nesting, trabecular, or gyriform patterns. The cells are 
relatively uniform and produce abundant neurosecretory granules, reflected in the strong 
and diffuse immunoexpression of neuroendocrine markers such as chromogranin A (CGA) 
and synaptophysin. Poorly differentiated NETs less closely resemble nonneoplastic 
neuroendocrine cells and have a more sheet-like or diffuse architecture, irregular nuclei, and 
less cytoplasmic granularity. Immunoexpression of neuroendocrine markers is usually more 
limited. Grade, on the other hand, refers to the inherent biologic aggressiveness of the 
tumor. Low-grade NETs are relatively indolent, high-grade tumors are extremely 
aggressive, and intermediate-grade examples have a less predictable, moderately aggressive 
course. In general, well-differentiated NETs are either low or intermediate grade, and poorly 
differentiated NETs are considered high grade in all cases (Table 3 ) (18-22).  
 
Differentiation Grade 
Well differentiated 
Low grade (ENETS G1) 
Intermediate grade (ENETS G2) 
Poorly differentiated High grade (ENETS G3) 
Table 3. Differentiation of gastric NETs  
 
Grade 
Lung, Thymus 
(WHO) 
GEP NETs 
(ENETS) 
GEP NETs (WHO 2010) 
Low grade Carcinoid tumor NET grade 1 (G1) 
Neuroendocrine 
neoplasm grade 1 
Intermediate 
grade 
Atypical carcinoid 
tumor 
NET grade 2 (G2) 
Neuroendocrine 
neoplasm grade 2 
High grade 
Small cell 
carcinoma 
Neuroendocrine 
carcinoma grade 3 
(G3), small cell 
carcinoma 
Neuroendocrine 
carcinoma grade 3, 
small cell carcinoma 
Large cell 
neuroendocrine 
carcinoma 
Neuroendocrine 
carcinoma grade 3 
(G3), large cell 
neuroendocrine 
Neuroendocrine 
carcinoma grade 3, 
large cell 
neuroendocrine 
carcinoma 
The grade of the tumor must be included in the pathology report, along with a reference 
to the specific grading system being used. Unqualified terms such as neuroendocrine 
tumor or neuroendocrine carcinoma without reference to grade do not provide adequate 
pathology information. 
Table 4. Differentiation of gastric Nets (2)  
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Table 4 displays a comparison of the various systems of nomenclature currently in use for 
NETs, along with for which organ systems each system is most commonly used. 
Figures 1-3 are presenting histology evaluation of neuroendocrine gastric carcinoma-large 
cell type, that demonstrates trabecula and islet of round cells with rare eosinophilic 
cytoplasm. The nuclei are atypical, hyperchromatic, moderately pleomorphic, without 
prominent nucleolus. The stroma is edematous. Vascular invasion in mucosa and 
submucosa is also detected ( Stained H&E - Figure 1). Cytological immunophenotypes 
includes: marked and diffuse immunoreactivity in the majority of the cells to neuron 
specific-enolase (NSE) – ( Figure 2), chromogranin A( Figure 3 ) and synaptophysin.  
 
 
Fig. 1. Neuroendocrine gastric carcinoma-large cell type, Stained H&E, x400. Courtesy by 
Prof S.Usaj 
The American Joint Committee on Cancer (AJCC) has recently published a new TNM 
staging manual that includes NETs of all anatomical sites, and the ENETS has previously 
published recommendations for TNM staging of GEP NETs. dditionally, the staging criteria 
for both systems rely predominantly on the size of the tumor and the extent of invasion into 
similar landmarks as used for the staging of nonneuroendocrine carcinomas of the same 
sites. It is recommended that the extent of involvement of these structures be specifically 
indicated in the pathology reports, in addition to providing a TNM stage based on a system 
that is specifically referenced (Table 5) (23-26). Figures 4 and 5 represent T2 and M1 GEP 
NET thru the EUS image. 
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Fig. 2. Neuroendocrine tumor cells of the stomach wall -Immunostaining - NSE (LSAB+ , 
x200). Courtesy by Prof S.Usaj 
 
 
Fig. 3. Neuroendocrine tumor cells of the stomach wall- Immunostaining - chromogranin A  
(LSAB+ , x200). Courtesy by Prof S.Usaj 
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AJCC 
Primary tumor (T) 
ENETS 
T-Primary Tumor 
TX Primary tumor cannot 
be assessed 
TX Primary tumor cannot be 
assessed 
T0 No evidence of primary 
tumor 
T0 No evidence of primary 
tumor 
Tis Carcinoma in 
situ/dysplasia (tumor 
size <0.5mm), confined 
to mucosa 
__  
T1 Tumor invades lamina 
propria or submucosa 
and ≤ 1 cm 
T1 Tumor invades lamina 
propria or submucosa 
and ≤ 1 cm 
T2 Tumor invades 
muscularis propria or > 
1 cm 
T2 Tumor invades 
muscularis propria or > 1 
cm 
T3 Tumor penetrates 
subserosa 
T3 Tumor invades pancreas 
or retroperitoneum 
T4 Tumor invades serosa 
(visceral peritoneum) or 
other organs or adjacent 
structures 
T4 Tumor invades 
peritoneum or other 
organs 
Regional Lymph nodes 
(N) 
 N-Regional Lymph 
Nodes 
 
NX Regional lymph node(s) 
cannot be assessed 
NX Regional lymph node(s) 
cannot be assessed 
N0 No regional lymph 
node metastasis 
N0 No regional lymph node 
metastasis 
N1 Regional lymph node 
metastasis 
N1 Regional lymph node 
metastasis 
Distant metastasis (M)  M-distant metastasis  
__  MX Distant metastasis cannot 
be assessed 
M0 No distant metastasis M0 No distant metastasis 
M1 Distant metastasis M1 Distant metastasis 
Stage T N M Stage T N M 
0 Tis N0 M0 0 Tis N0 M0 
I T1 N0 M0 I T1 N0 M0 
IIA T2 N0 M0 IIa T2 N0 M0 
IIB T3 N0 M0 IIb T3 N0 M0 
IIIA T4 N0 M0 IIIa T4 N0 M0 
IIIB Any T N1 M0 IIIb Any T N1 M0 
IV Any T Any N M1 IV Any T Any N M1 
Table 5. The TNM NETs classification 
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Fig. 4. EUS image: T2 tumor of the stomach wall. Courtesy by Prof M.Krstic 
 
 
Fig. 5. EUS image of enlarged lymph nodes around the tumor (see white arrows). Courtesy 
by Prof M.Krstic 
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6. Imaging 
Most NETs of the stomach are directly imaged and diagnosed during endoscopy. For larger 
lesions, endoscopic ultrasound (EUS) may be performed to assess whether the NETs of the 
stomach is invasive. Cross-sectional imaging with computed tomography (CT) or magnetic 
resonance imaging (MRI) is recommended to assess for metastases in patients with type 1 or 
2 NETs of the stomach more than 2 cm in diameter, or for patients with type 3 NETs of the 
stomach in whom metastatic risk is a concern. Neuroendocrine tumors are generally 
vascular tumors that enhance intensely with intravenous contrast during early arterial 
phases of imaging with washout during the delayed portal venous phase. The key to 
detecting small NETs on CT is to maximize the contrast between the tumor and the adjacent 
normal parenchyma. For abdominal and pelvic imaging, recommendation is multiphasic CT 
that includes the arterial phase and the portal venous phase. Rapid intravenous bolus of 
intravenous contrast is also recommended. Thin sectioning and the use of a negative oral 
contrast agent also may be helpful in detecting small primary tumor in the small bowel that 
may not otherwise be seen. Magnetic resonance imaging is preferred over CT for patients 
with a history of allergy to iodine contrast material or for those with renal insufficiency. 
Somatostatin receptor scintigraphy (SRS) provides a second useful imaging modality for the 
detection of metastatic disease in patients with malignant NETs of the stomach. Indium In 
111-labeled somatostatin analog [111In-DTPA0]octreotide was developed for scintigraphy of 
NETs. It shares the receptor-binding profile of octreotide, which makes it a good 
radiopharmaceutical for imaging of somatostatin receptor 2- and receptor 5-positive tumors. 
The overall sensitivity of [111In-DTPA0]octreotide scintigraphy seems to be about 80% to 
90%. Unlike cross-sectional imaging, which is generally site directed, [111In-
DTPA0]octreotide scintigraphy is done as whole-body imaging and thus can detect disease 
at unsuspected sites. Chest x-ray can be used as a screening examination for patients 
without evidence of thoracic disease (27,29). 
7. Biochemical monitoring 
Fasting serum gastrin levels are important to differentiate types 1 and 2 NETs of the 
stomach from type 3. 5-Hydroxyindoleacetic acid (5-HIAA) levels are generally not useful in 
patients with NETs of the stomach, because development of the carcinoid syndrome is 
uncommon. Furthermore, carcinoid syndrome, if it occurs in these patients, is reported to be 
characteristically atypical with normal serotonin and 5-HIAA levels, although a recent study 
reports the typical carcinoid syndrome can occur in rare patients with NETs of the stomach. 
Plasma CGA levels are recommended because CGA is frequently elevated in both patients 
with types 1 and 2 as well as type 3 NETs of the stomach, and changes in CGA levels may be 
helpful in the follow-up. Chromogranin A should be used with caution as a marker of 
disease activity in patients treated with somatostatin analogs, because these agents 
significantly reduce plasma CGA levels, a change that may be more reflective of changes in 
hormonal synthesis and release from tumor cells than an actual reduction in tumor mass.  In 
patients on stable doses of somatostatin analogs, consistent increases in plasma CGA levels 
over time may reflect loss of secretory control and/or tumor growth. Plasma CGA levels 
have also been shown to have a prognostic value in patients with metastatic disease 
(16,17,30,31).  
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8. Management of localized NETs of the stomach 
Because types 1 and 2 NETs of the stomach generally pursue an indolent course, tumors less 
than 2 cm (up to 6) should be resected endoscopically, with subsequent interval follow-up 
(15,27,32). Patients with tumors measuring more than 2 cm, with recurrent tumors or with 
more than 6 polyps, generally require more aggressive management, and local surgical 
resection is recommended. In patients with type 1 NETs of the stomach arising in the setting 
of chronic atrophic gastritis, antrectomy may be performed to eliminate the source of gastric 
production. Antrectomy has been reported to result in tumor regression in such cases. In 
patients with type 2 NETs of the stomach secondary to ZES/MEN I syndrome, treatment 
with somatostatin analogs may be initiated and has resulted in tumor regression.(33-35) The 
surgical management of type 3 isolated sporadic NETs of the stomach requires more 
aggressive surgery, generally with partial gastrectomy and lymph node dissection (Table 6). 
Surgery is the only therapy that can cure GEP-NETs. However, the typical delay in 
diagnosis, giving the tumor the opportunity to metastasize, makes most GEP-NETs 
ineligible for surgery (non-resectable). The most common nonsurgical therapy for all GEP-
NETs is chemotherapy, although chemotherapy is reported to be largely ineffective for 
carcinoids, not particularly durable (long-lasting) for PETs, and inappropriate for PETs of 
nonpancreatic origin. When chemotherapy fails, the most common therapy, in the United 
States, is more chemotherapy, with a different set of agents. Some studies have shown that 
the benefit from one agent is not highly predictive of the benefit from another agent, except 
that the long-term benefit of any agent is likely to be low. Strong uptake of somatostatin 
analogs is a negative indication for chemo. There are two major somatostatin-analog-based 
targeted therapies. The first of the two therapies provides symptomatic relief for patients 
with secretory tumors. In effect, somatostatin given subcutaneously or intramuscularly 
 
 
 Size, cm 
No. 
tumors 
Therapy Clinical Features 
Type 1 (in setting 
of chronic 
atrophic gastritis 
type A) 
< 2 < 6 
Resected 
endoscopically Rarely invasive; endoscopic 
removal often adequate 
> 2 > 6 
Local surgical 
resection/antrectomy
Type 2 (in setting 
of ZES) 
< 2 < 6 
Resected 
endoscopically Rarely invasive; may 
respond to somatostatin 
analogs > 2 > 6 
Local surgical 
resection/antrectomy
Type 3 (sporadic) > 1 Solitary 
Partial gastrectomy 
and lymph nodes 
resection 
Frequently invasive and 
metastatic-Chemotherapy, 
chemotherapy with 
different agents  
Table 6. Management of localized NETs of the stomach 
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"clogs up" the receptors, blocking the secretion of hormones from the tumor cells. The 
second of the two major somatostatin-analog-based targeted therapies is called peptide 
receptor radionuclide therapy (PRRT), though we might simply call it hormone-delivered 
radiotherapy. In this form of radioisotope therapy (RIT), radioactive substances (called 
radionuclides or radioligands) are chemically conjugated with hormones (peptides or 
neuroamines); the combination is given intravenously to a patient who has good uptake of 
the chosen hormone. The radioactive labelled hormones enter the tumor cells, and the 
attached radiation damages the tumor- and nearby cells. Not all cells are immediately killed 
this way. The process of tumor cells dying as result of this therapy can go on for several 
months, even up to two years. In patients with strongly overexpressing tumor cells, nearly 
all the radiation either gets into the tumors or is excreted in urine (10). 
9. Management of metastatic NETs of the stomach 
In general, metastatic NETs of the stomach, which are infrequent and therefore usually 
included in general studies including other more frequent malignant carcinoids (especially 
midgut), are treated in a similar fashion as these other malignant carcinoids. It has been 
proposed for the occasional, younger patient without any of these risk factors with a 
metastatic carcinoid tumor that is unresectable and limited to the liver that liver 
transplantation remains an option that should be considered (Table 7). 
10. Hepatic resection and transplantation 
A small percentage of patients (5%-15%) with metastatic liver disease with a limited number 
of hepatic metastases localized preferable to one lobe may be successfully treated with 
hepatic resection, providing both long-term symptomatic relief and likely increasing 
survival times. The number of patients with liver-isolated metastatic NETs in whom 
orthotopic liver transplantation (OLT) has been attempted remains small, resulting in the 
role of OLT in such patients being controversial and cannot, at this time, be routinely 
recommended (36-38). 
11. Hepatic artery embolization 
Hepatic arterial embolization is recommended as a palliative option in patients with 
hepatic metastases who are not candidates for surgical resection, have an otherwise 
preserved performance status, have disease primarily confined to the liver, and have a 
patent portal vein. The response rates associated with embolization, as measured either by 
decrease in hormonal secretion or by radiographic regression, are generally greater than 
50% (39-41).  
12. Cytotoxic chemotherapy 
Because of its rarity, there have not been any specific studies of cytotoxic agents in only 
patients with malignant NETs of the stomach. However, with malignant carcinoids in 
general, cytotoxic chemotherapy plays only a limited role, and therefore, it is probable that 
similar results can be expected with malignant NETs of the stomach. Studies of single-agent 
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therapy with 5-fluorouracil, streptozocin, or doxorubicin in patients with metastatic 
carcinoid tumors have shown that these agents are associated with only modest response 
rates (41,42).  
13. Systemic treatment of metastatic disease 
Patients with metastatic NETs of the stomach may develop an "atypical" carcinoid syndrome 
related to release of histamine and/or 5-HTP or rarely a typical carcinoid syndrome as seen 
in patients with metastatic midgut carcinoids. These patients frequently benefit from 
treatment with somatostatin analogs for symptom control. The addition of α-interferon to 
therapy with somatostatin analogs has been reported to be effective in controlling 
symptoms in patients with carcinoid syndrome who may be resistant to somatostatin 
analogs alone. Treatment with α-interferon may therefore be considered in patients with 
metastatic NETs of the stomach refractory to somatostatin analogs. In clinical trials, doses of 
α-interferon have ranged from 3 to 9 MU subcutaneously, administered from 3 to 7 times 
per week. The direct antineoplastic effects of somatostatin analogs either with or without 
interferon remain uncertain, although recent studies suggest they have a cytostatic effect in 
40% to 70% of patients (41,42). 
 
 
 
 
 
Metastasis or non 
resectable GEP 
NETs 
Hepatic resection 
and transplantation 
Hepatic Artery 
Embolization 
Cytotoxic 
Chemotherapy 
Systemic treatment 
of metastatic 
disease-
somatostatin 
analogs, interferon 
Radiofrequency 
Ablation and 
Cryoablation 
 
 
 
Table 7. Management of metastatic NETs of the stomach 
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14. Radiofrequency ablation and cryoablation 
Other approaches to the treatment of hepatic metastases include the use of radiofrequency 
ablation (RFA) and cryoablation, either alone or in conjunction with surgical debulking. 
These approaches can be performed using a percutaneous or laparoscopic approach. 
15. Summary and conclusions 
To conclude, neuroendocrine tumors are small, slow-growing neoplasms, usually with 
episodic expression that makes diagnosis difficult, erroneous, and often late; for these 
reasons, a high index of suspicion is needed, and it is important to understand the 
pathophysiology of each tumor to decide which biochemical markers are more useful and 
when they should be used. It is the purpose of this text to show the importance of 
recognizing, as early as possible, the clinical syndromes that suggest a NET as one of the 
differential diagnoses, and once suspected, look for the appropriate biochemical markers 
and radiological or other means that will confirm the diagnosis or confidently discard it. 
Ultimately, all 3 modalities are important to create a platform for monitoring response to 
therapy, determining prognosis, and choosing the right therapeutic intervention (43).  
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